Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Magnetic Resonance (MR) Guided Focused Ultrasound in the Treatment of Brain Tumors (FUS-Tumor)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01698437
Recruitment Status : Completed
First Posted : October 3, 2012
Last Update Posted : June 3, 2016
Information provided by (Responsible Party):
University Children's Hospital, Zurich

Brief Summary:
Focused Ultrasound Focused ultrasound is an attractive method for non-invasive thermal ablation of soft tissue tumors. Treatment begins by acquiring a series of MR images of the target organ. The physician then identifies a target volume in the MR images and delineates the treatment contours on the images. Therapy planning software calculates the parameters required to effectively treat the defined target volume. During the treatment an ultrasound transducer generates and focuses ultrasound energy to a focal point, called a sonication. The sonication raises the tissue temperature within a well-defined region to a degree, which causes thermal coagulation. MR images acquired during sonication provide a quantitative, real-time temperature map of the target area to confirm the location of the sonication and the size of the coagulated region. The sonication process is repeated at multiple adjacent points to cover the entire prescribed treatment volume.

Condition or disease Intervention/treatment Phase
Malignant Brain Tumors Device: Non-invasive intervention with focused ultrasound (ExAblate 4000) Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 3 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: MR-guided Ultrasound-Neurosurgery for the Treatment of Malignant Brain Tumors
Study Start Date : February 2011
Actual Primary Completion Date : May 2016
Actual Study Completion Date : May 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Brain Tumors

Arm Intervention/treatment
Transcranial MR-Guided Focused Ultrasound for Brain Tumors Device: Non-invasive intervention with focused ultrasound (ExAblate 4000)
Non-invasive brain intervention using MR-guided focused ultrasound
Other Name: ExAblate 4000

Primary Outcome Measures :
  1. Lesion Size [ Time Frame: 3 months ]
    Size of lesion in the tumor tissue for each sonication as a function of applied energy/temperature.

  2. Patient Safety [ Time Frame: 3 months ]
    Number of Participants with Adverse Events as a Measure of Safety and Tolerability.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male or female ages over 18 years old that give informed written consent to participate in study. Females in reproductive age have to provide a negative serum pregnancy test.
  2. Patients with primary diagnosis (biopsy proven) of a malignant glioma or a recurrent glioma, that do not accept a conventional tumor resection or where a conventional tumor resection is not indicated according to both the neurosurgeon in charge and the neuro-oncology colloquium at the Kantonsspital Aarau.


    Patients with a supratentorial brain metastasis of a malignant tumor, that do not accept a conventional tumor resection or where a conventional tumor resection is not indicated according to the neurosurgeon in charge and the neuro-oncology colloquium at the Kantonsspital Aarau.

  3. The portion of the tumor to be treated during one intervention is less than 3.0 cm in diameter, corresponding to a volume of ca. 14 cc.

    If the total size of the tumor is larger than 3.0 cm in diameter then eventual complementing ablations will not be performed before 2 week after the first treatment.

  4. The tumor to be treated is clearly defined and can be well distinguished from surrounding brain tissue.
  5. The border of the targeted tumor volume has in all directions a distance of at least 2.5 cm from the inner table of the skull. Portions of the tumor that are not planned to be treated due to this safety margin will be marked.
  6. Patients must have an ASA score 1-2, and a Karnofsky score 70-100

Exclusion Criteria:

All tumor Types

  1. Clinical or neuroradiological signs of increased intracranial pressure.
  2. Significantly increased vascularization of tumor in preoperative MR-angiogram or in digital subtraction angiography (DSA).
  3. Tumor mass effect that causes midline shift or a shift of the third (3rd) ventricle of more than 5 mm, even after steroid therapy.
  4. The border of the tumor portion to be treated is less then 5mm away from a main branch of a brain vessel, the venous sinuses, the pituitary gland or the cranial nerves.
  5. The tumor is in immediate proximity to a cystic formation.
  6. Recent (less than 2 weeks) intracranial hemorrhage.
  7. Increased risk of bleeding: platelets < 100,000/mm3, INR > 1.3 or other coagulation disorders.
  8. Tumors with presumably high risk of bleeding
  9. Oral anticoagulant or thrombocyte aggregation suppression (e.g. ASS) that was not stopped at least 5 days before the intervention.
  10. Contraindication for MR-exams, such as non-MR-compatible implants or cardiac pacemaker.
  11. Clips and other implants in the sonication path or in the target area.
  12. Operation implants such as dura patch, skull reconstruction with polymethylmethacrylate (PalacosTM), titan in the sonication path.
  13. Infratentorial (i.e. cerebellar-) tumors.
  14. Contraindications for MR-contrast agents or for steroid therapy
  15. Allergy against local anesthesia.
  16. Uncontrolled arterial hypertension.
  17. Other life threatening diseases.
  18. Severe uncontrolled systemic infection.
  19. Hypersensitivity to contrast agents used in this study.
  20. Severely impaired renal function (estimated glomerular filtration rate < 30 mL/min/1.73 m2) or under dialysis.
  21. Inability to give informed written consent.
  22. Alcohol or drug abuse.
  23. Patients who are unreliable and will not appear for the follow up exams.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01698437

Layout table for location information
MR-Center, University Children's Hospital
Zurich, Switzerland
Sponsors and Collaborators
University Children's Hospital, Zurich
Layout table for investigator information
Principal Investigator: Javier - Fandino, MD Dept. of Neurosurgery, Kantonsspital Aarau, 5001 Aarau, Switzerland
Principal Investigator: Ernst - Martin, MD Center for MR-Research, University Children's Hospital Zurich, Switzerland
Layout table for additonal information
Responsible Party: University Children's Hospital, Zurich Identifier: NCT01698437    
Other Study ID Numbers: AG2010/026,ZH 2010-0543/3
First Posted: October 3, 2012    Key Record Dates
Last Update Posted: June 3, 2016
Last Verified: June 2016
Keywords provided by University Children's Hospital, Zurich:
focused ultrasound
functional brain disorders
neuropathic pain
movement disorders
malignant of brain tumors
Additional relevant MeSH terms:
Layout table for MeSH terms
Brain Neoplasms
Central Nervous System Neoplasms
Nervous System Neoplasms
Neoplasms by Site
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases